Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Aspen Pharmacare Holdings Limited (APN.JO)

Johannesburg - Johannesburg Delayed Price. Currency in ZAc
Add to watchlist
23,495.00-40.00 (-0.17%)
At close: 05:04PM SAST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close23,535.00
Open24,193.00
Bid23,375.00 x 0
Ask24,000.00 x 0
Day's Range23,412.00 - 24,203.00
52 Week Range12,200.00 - 28,167.00
Volume878,075
Avg. Volume1,494,021
Market Cap10.702T
Beta (5Y Monthly)0.72
PE Ratio (TTM)2,339.67
EPS (TTM)10.04
Earnings DateSep 01, 2021
Forward Dividend & Yield2.62 (1.14%)
Ex-Dividend DateSep 21, 2021
1y Target EstN/A
  • Reuters

    REFILE-UPDATE 3-S.Africa's Aspen signs deal paving way for J&J COVID vaccine licence

    South Africa's Aspen Pharmacare took a step towards a licensing deal to package and sell Johnson & Johnson's COVID-19 vaccine in Africa, announcing on Tuesday it had signed non-binding terms with subsidiaries of the U.S. drugmaker. While Aspen did not give a firm date on when it expects the deal to be finalised, Stephen Saad, chief executive of Aspen, told Reuters he is "hoping to get this (deal) out as soon as possible in 2022."

  • Reuters

    S.Africa's Aspen signs non-binding agreement with J&J for COVID vaccine license

    South Africa's Aspen Pharmacare on Tuesday signed a non-binding agreement with subsidiary firms of U.S. company Johnson & Johnson as part of its negotiations for a licensing deal to package, market and sell the latter's COVID-19 vaccine in Africa, it said in a statement. Aspen currently packages J&J's COVID-19 vaccine at its South African plant under contract, which means it does not have any pricing or distribution power over the product.

  • Reuters

    UPDATE 1-South Africa's Aspen in advanced talks over COVID-19 vaccine deal

    Aspen Pharmacare is in advanced discussions over a potential licensing agreement to package the COVID-19 vaccine in South Africa, it said on Monday. The South African company did not mention the name of the company with which it was in talks, but in early September it said it was in talks with U.S. pharma giant Johnson & Johnson over a vaccine packaging licence. Aspen currently packages J&J's COVID-19 vaccine at its South African plant under contract, which means it does not have any pricing or distribution power over the product.

Advertisement
Advertisement